• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Atreca Inc.

    3/11/24 4:12:26 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email
    DEFA14A 1 tm248437d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.     )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

      Atreca, Inc.  
      (Name of Registrant as Specified in Its Charter)  
         
         
      (Name of Person(s) Filing Proxy Statement, if other than the Registrant)  

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) 
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 8, 2024

     

     

     

    Atreca, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware 001-38935 27-3723255

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

         
    900 E. Hamilton Ave., Suite 100
    Campbell, California
      95008
    (Address of Principal Executive Offices)   (Zip Code)

     

    (650) 595-2595 

    (Registrant’s Telephone Number, Including Area Code)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, $0.0001 par value per share   BCEL   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously reported, on September 8, 2023, Atreca, Inc. (the “Company”) received written notification (the “Initial Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying it that on September 7, 2023, the average closing price of the Company’s Class A common stock, $0.0001 par value per share (the “Class A Common Stock”), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”).

     

    In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the “Grace Period”), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period.

     

    On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the “SEC”) to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter.

     

    The Company expects that its Class A Common Stock will be eligible to be quoted “over-the-counter,” however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the delisting and trading suspension of the Company’s Class A Common Stock from Nasdaq, the deregistration of the Class A Common Stock and the suspension of the Company’s reporting obligations pursuant to the Securities Exchange Act of 1934, as amended, and the timing of such matters, and the quotation of the Class A Common Stock on an over-the-counter market or any other quotation medium. These forward-looking statements are based on the current beliefs and expectations of the Company’s management team and are inherently subject to uncertainties and changes in circumstances. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the risks and uncertainties included under the header “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the SEC on November 14, 2023 and the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on February 23, 2024. Copies of reports and other filings the Company files with the SEC are available on the SEC’s website at www.sec.gov and posted on its website. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update any forward-looking statement in this Current Report on Form 8-K, except as required by law.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Atreca, Inc.
       
       
    Dated: March 11, 2024 By: /s/ Courtney J. Phillips
        Courtney J. Phillips
        General Counsel and Corporate Secretary

     

     

     

    Get the next $BCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCEL

    DatePrice TargetRatingAnalyst
    3/4/2022$17.00 → $14.00Buy
    Stifel
    More analyst ratings

    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

    4 - Atreca, Inc. (0001532346) (Issuer)

    4/17/24 7:36:28 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)

    4 - Atreca, Inc. (0001532346) (Issuer)

    4/3/24 9:50:22 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)

    4 - Atreca, Inc. (0001532346) (Issuer)

    4/3/24 9:37:17 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel reiterated coverage on Atreca with a new price target

    Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

    3/4/22 7:37:56 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird resumed coverage on Atreca with a new price target

    Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously

    6/4/21 7:01:08 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Atreca with a new price target

    Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00

    2/8/21 5:57:56 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    SEC Filings

    View All

    SEC Form DEFM14A filed by Atreca Inc.

    DEFM14A - Atreca, Inc. (0001532346) (Filer)

    4/22/24 9:21:58 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PREM14A filed by Atreca Inc.

    PREM14A - Atreca, Inc. (0001532346) (Filer)

    4/11/24 4:52:06 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Atreca Inc.

    15-12G - Atreca, Inc. (0001532346) (Filer)

    4/1/24 4:31:35 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunome to Acquire Antibody-Related Assets and Materials from Atreca

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass

    12/26/23 8:30:00 AM ET
    $BCEL
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

    CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com

    12/26/23 8:30:00 AM ET
    $BCEL
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

    SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no

    11/14/23 4:30:08 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

    4 - Atreca, Inc. (0001532346) (Issuer)

    4/17/24 7:36:28 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Financials

    Live finance-specific insights

    View All

    Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

    ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

    3/29/23 4:05:12 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

    SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

    3/23/23 5:00:36 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atreca Announces Expansion of Preclinical Pipeline

    Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

    4/5/22 4:01:00 PM ET
    $BCEL
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

    SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a

    1/9/23 8:30:54 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

    - Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to

    6/27/22 8:00:00 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

    SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele

    6/16/22 4:05:22 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Atreca Inc.

    SC 13G - Atreca, Inc. (0001532346) (Subject)

    1/10/24 4:52:48 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

    SC 13G/A - Atreca, Inc. (0001532346) (Subject)

    12/7/22 10:24:32 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

    SC 13G/A - Atreca, Inc. (0001532346) (Subject)

    2/14/22 4:47:03 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care